< Back to H.R. 1254 (112th Congress, 2011–2013)

Text of the Synthetic Drug Control Act of 2011

This bill was introduced in a previous session of Congress and was passed by the House on December 8, 2011 but was never passed by the Senate. The text of the bill below is as of Mar 30, 2011 (Introduced).

This is not the latest text of this bill.

Download PDF

Source: GPO

I

112th CONGRESS

1st Session

H. R. 1254

IN THE HOUSE OF REPRESENTATIVES

March 30, 2011

(for himself, Mr. Meehan, Mr. Marino, Mr. Platts, Mr. Barletta, Mr. Cuellar, Mrs. Emerson, Mrs. Biggert, Mr. LaTourette, Mr. Gibson, Mr. Stivers, and Mr. Reed) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

1.

Short title

This Act may be cited as the Synthetic Drug Control Act of 2011.

2.

Addition of synthetic drugs to Schedule I of the Controlled Substances Act

(a)

Cannabimimetic agents

Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end the following:

(d)
(1)

Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

(2)

In paragraph (1), the term cannabimimetic agents

(A)

means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within the following structural classes:

(i)

2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.

(ii)

3-(1-naphthoyl)indole or 3-(1-naphthyl)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.

(iii)

3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.

(iv)

1-(1-naphthylmethyl)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.

(v)

3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.; and

(B)

includes—

(i)

5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);

(ii)

5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog);

(iii)

1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);

(iv)

1-butyl-3-(1-naphthoyl)indole (JWH-073);

(v)

1-hexyl-3-(1-naphthoyl)indole (JWH-019);

(vi)

1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

(vii)

1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

(viii)

1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);

(ix)

1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

(x)

1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

(xi)

1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);

(xii)

1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);

(xiii)

1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4);

(xiv)

1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8); and

(xv)

1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).

.

(b)

Other drugs

Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:

(18)

4-methylmethcathinone (Mephedrone).

(19)

3,4-methylenedioxypyrovalerone (MDPV).

(20)

3,4-methylenedioxymethcathinone (methylone).

(21)

Naphthylpyrovalerone (naphyrone).

(22)

4-fluoromethcathinone (flephedrone).

(23)

4-methoxymethcathinone (methedrone; Bk-PMMA).

(24)

Ethcathinone.

(25)

3,4-methylenedioxyethcathinone (ethylone).

(26)

Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone).

(27)

N,N-dimethylcathinone (metamfepramone).

(28)

Alpha-pyrrolidinopropiophenone (alpha-PPP).

(29)

4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP).

(30)

3,4-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP).

(31)

Alpha-pyrrolidinovalerophenone (alpha-PVP).

(32)

6,7-dihydro-5H-indeno(5,6-d)-1,3-dioxal-6-amine) (MDAI).

.

3.

Temporary scheduling to avoid imminent hazards to public safety expansion

Section 201(h)(2) of the Controlled Substances Act (21 U.S.C. 811(h)(2)) is amended—

(1)

by striking one year and inserting 2 years; and

(2)

by striking six months and inserting 1 year.